GlassScriptPhysician profile
Celine Leung
NPI 1477970630
$1,468.92
in general payments reported to CMS, 2019-2025
22 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.91 · 2021: $150 · 2022: $213 · 2023: $281 · 2024: $409 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $303.10 | 2021-2025 | |
| Abbvie INC. | $220.33 | 2024-2025 | |
| Ucb, INC. | $133.55 | 2023-2025 | Briviact, Nayzilam |
| Jazz Pharmaceuticals INC. | $129.38 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $112.14 | 2024-2025 | Qelbree |
| Amgen INC. | $99.18 | 2022 | |
| Pfizer INC. | $85.89 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.97 | 2022 | |
| Otter Pharmaceuticals, LLC | $46.32 | 2025 | Sympazan |
| Neurelis, INC. | $44.84 | 2024-2025 | Valtoco |
| Greenwich Biosciences, INC. | $39.37 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $34.53 | 2024 | Relexxii |
| Aucta Pharmaceuticals, INC. | $20.73 | 2024 | Motpoly Xr |
| Sunovion Pharmaceuticals INC. | $20.42 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.68 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $18.34 | 2025 | Brekiya |
| Tris Pharma INC | $15.99 | 2025 | Onyda Xr |
| Impel Pharmaceuticals INC. | $15.55 | 2022 | |
| Collegium Pharmaceutical, INC. | $13.67 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.54 | 2025 | Ajovy |
| Aquestive Therapeutics, INC. | $13.39 | 2021 | |
| Lilly USA, LLC | $13.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celine Leung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.